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There is strong evidence from multiple epidemological studies that lower urinary tract symptoms
(LUTS) and erectile dysfunction (ED) are correlated, independent of age or comorbidities as diabetes
or hypertension. Although a direct causal relationship is not established yet, four pathophysio
logical mechanisms can explain the relationship. These include alteration in nitric oxide
bioavailability, a1-adrenergic receptor hyperactivity, pelvic atherosclerosis and sex hormones.
This association has different clinical implications on the management of both disorders. Men
seeking care for one condition should always be screened for complaints of the other condition.
Sexual function should be assessed and discussed with the patient when choosing the appropriate
management strategy for LUTS, as well as when evaluating the patient’s response to treatment.
Multiple large clinical trials have shown an improvement in LUTS after phosphodiesterase-5
(PDE5)-inhibitor treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in
conjunction with existing therapies or as a primary treatment. There may be a potential therapeutic
role for testosterone in LUTS treatment in cases of testosterone deficiency that needs to be
investigated. Much further investigation is required, but it is evident that the association between
LUTS and ED is fundamental for future therapies and possible preventative strategies.
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Introduction
In recent years, increasing attention has been given
to the interaction and relationship between lower
urinary tract symptoms (LUTS) and erectile dys-
function (ED). Both complaints are highly prevalent
in the aging male and share common risk factors,
such as hypertension, hypercholesterolemia
and diabetes mellitus. Aside from these common
denominators, an independent association has been
elucidated in a number of large-scale international
trials. There is a strong correlation between age and
ED, with prevalence increasing steadily from 6.5%
in men aged 20–39 years to 77.5% in those 75 years
and older.1 A similar increase in the prevalence of
LUTS in men has been observed from somewhato1
in 10 in men aged 30–39 years to 41 in 3 in men
aged 60–69 years.2 In total, as much as three in four
men are likely to experience LUTS sometime during
their lifespan.3 Both disorders have a major impact
on quality of life (QoL) on individual patients,
and further have a major socio-economic impact. In
this review, we focus on the epidemiological
and pathophysiological correlation of LUTS and
ED, and discuss the impacts of this association on
the clinical management of both disorders.
LUTS and ED: clinical and epidemiological
correlations
A large number of clinical population-based and
longitudinal studies have shown a strong correlation
between ED and LUTS. In the Cologne Male Survey,
a study including approximately 5000 German men
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aged 30–80 years, one in five subjects suffered from
ED.4 Interestingly, the prevalence of LUTS was 72%
in men with ED versus 38% in those without ED.4
Additional analyses employing multiple logical
regression showed that the presence of LUTS was
a risk factor for ED. Moreover, this relationship was
independent of the presence of other risk factors,
such as age, hypertension, diabetes and pelvic
surgery.5 The multinational survey of the aging male
is a multinational survey conducted to investigate
the relationship between LUTS and sexual problems
in aging men.6 In this study, 12 815 men aged 50–80
years in the United States and six European
countries were included.5 In this survey, Rosen
et al.6 indicated a link between ED and LUTS, with
ED being more prevalent in patients with increasing
LUTS complaints. To illustrate this relationship,
only a quarter of men who had no LUTS suffered
from ED, while four in five men with severe LUTS
had reduced or no erections. Similarly, it was shown
in the Cologne study that the relationship between
LUTS and sexual dysfunction was independent of
the effects of age, other comorbidities and lifestyle
factors. These results were corroborated by McVary
et al.,7 who reported a strong correlation between
baseline American Urological Association (AUA)
symptom index and the various domains of sexual
function. The association between LUTS and ED
was examined prospectively in 17 086 men in the
health professionals follow-up study. The risk of ED
increased with rising LUTS severity with stronger
correlation in younger than in older men.8 This
correlation was proved worldwide as evidenced by the
results of the Asian Survey of Aging Males study. This
survey was carried out in Asian men aged 50–80 years
from five Asian countries. The study results confirmed
the correlation with sexual disorders increased with
age and increasing severity of the LUTS. Erectile
and ejaculation problems were more common in men
with diabetes or hypertension. These two groups
(diabetic and hypertensive patients) showed higher
prevalence of ED and ejaculatory dysfunction. There
was a significant increase in abnormal and painful
ejaculation in men with hypertension.9
LUTS is typically classified in obstructive (void-
ing) symptoms and irritative (storage) symptoms.
While many of the above mentioned and other
studies have reported correlations of LUTS and ED,
only few reports have determined exactly what
LUTS domain is related to which aspect of erectile,
and more general, male sexual function. Standar-
dized questionnaires like the international prostate
symptom score (IPSS) for LUTS and the inter
national index of erectile function (IIEF), and its
abridged version (IIEF-5 or sexual health inventory
for men (SHIM)) for sexual and erectile function
have helped to clarify this relationship. If the
symptom(s) that should be addressed to improve
sexual function could be identified, more effective
treatments for patients with comorbid LUTS and ED
may lie ahead. A small number of studies have
shown that severity of sexual dysfunction in the
presence of LUTS was related more to the severity of
the voiding symptoms and QoL. Also, the improve-
ments in voiding symptoms, IPSS-QoL and uroflow
were significantly related to enhanced sexual func-
tion. In the US Veterans Administration Survey, a
total of 181 male veterans were asked to submit an
SHIM and an IPPS questionnaire. An inverse
correlation was observed between obstructive and
not the irritative LUTS and SHIM score across age
groups, indicating that those with worse obstructive
symptoms also suffered from worse ED, with the
strongest effect for men aged 60–70 years. Although
a small positive correlation between the urinary
flow rate and SHIM score and negative correlation
between the post-void residual volume and the
SHIM score were found, these results were not
statistically significant.10 In an Austrian study, in
2858 men aged 20–80 years, the presence of LUTS,
in particular voiding symptoms, nocturia and the
QoL impairment due to LUTS, was independent risk
factors for the presence of ED.11
This may be due to psychosocial factors or
pathophysiologic factor as the affection of penile
vascularity by lower urinary obstruction. Khan
et al.12 created partial bladder outlet obstruction
(BOO) by ligating the proximal urethra of adult male
rabbits. After 3–6 weeks, the experimental rabbit
corpora cavernosa showed increased collagen
deposition with loss of smooth muscle and loss of
staining for endothelin-1.
LUTS and ED: pathophysiological
correlations
The association between LUTS and ED has been
explained by four major common pathophysiologic
mechanisms. These changes include alteration in
nitric oxide (NO) bioavailablity, increased smooth
muscle contractility, atherosclerosis and changes
in circulating sex hormone levels. Risk factors for
ED are also risk factors for LUTS, and signaling
pathways and mechanisms of smooth muscle contr
action in the penis are comparable with those
mechanisms for smooth muscle contraction in the
bladder neck, prostate and urethra. Understanding
the common denominators of LUTS and ED may help
us in diagnosis and, more importantly, treatment
choice. Studies in both animal models and humans
have contributed significantly to our understanding of
the relationship between these two entities.
Altered NO levels
NO has been identified as the capital signaling
molecule for penile erection. The discovery of the
NO signaling pathway in penile tissue has led to a
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revolution in ED research and to the development of
phosphodiesterase-5 (PDE5) inhibitors, which now
constitute first-line therapy for men with ED.13
In recent years, it has been recognized that reduced
NO availability is linked to the development of
prostate gland hyperplasia and the subsequent
development of LUTS. As a logical result, there is
an increasing interest in the NO pathway as a
potential pharmacological target to treat male LUTS.
Nitric oxide synthase (NOS) is found in the normal
prostate in two isoforms: endothelial NOS in the
endothelial cells and under the form of neuronal
NOS not only in nerve fibers transversing the
fibromuscular prostatic stroma, but also, interest-
ingly, in the cytoplasm of the basal cells.14,15 It has
been reported that NOS expression, and thus NO
production, of the prostate is reduced in the
transition zone of the prostate in benign prostatic
hyperplasia (BPH), compared with normal prostate
tissue.16 The proposed reduction in expression of
NOS isoforms results in increased smooth muscle
cell contractile forces at the bladder neck and
prostatic urethra. Additionally, the resulting NO
bioavailability results in prostatic smooth muscle
cell proliferation, which further contributes to
increased outlet resistance. Putative mechanisms
responsible for this decrease in NOS bioavailability
include accelerated breakdown of NO by reactive
oxygen species, and alterations in the phosphoryla-
tion and expression of NOS isoforms.17,18
An in vitro model demonstrated an anti-prolifera-
tive effect on human prostatic smooth muscle cells
by NO donors (sodium nitroprusside), increased cell
proliferation with NO antagonists and a negative
effect on the proliferation signal transduction path-
way (protein kinase C) with sodium nitroprusside.19
In vivo animal studies also suggest that NO has a
role in preventing bladder contractions that result in
bladder hyperactivity, the physiological correlate of
irritative LUTS. Neuronal NOS knock-out mice were
shown to have hypertrophied and dilated bladders
and dysfunctional urinary tract outlets, which did
not relax to electrical field stimulation or L-arginine,
a precursor of NO. These mice displayed increased
frequency of micturition.20 In another study, block-
ade of the NO pathway influenced the function of
the lower urinary tract, as studied by cystometry in
conscious rats and in vitro, in isolated muscle strips
from the rat detrusor and urethra.21
The theory that NO has a role in the development
of LUTS is further supported by the characterization
and functional relevance of PDE isoenzymes in
the human prostate, urethra and bladder wall.22
Importantly, this also opens the avenue toward a
potential benefit of PDE5-inhibitor therapy in LUTS.
In rats, PDE5 expression is highest in the bladder,
where it is expressed approximately 10-fold more
than in the rat corpus cavernosum.23 In an in vivo
BOO model in which rat urethras were narrowed
with a silk ligature was used, chronic treatment with
10mg kg–1 per day of vardenafil significantly
reduced bladder nonvoiding contractions by 47%
compared with placebo. Tamsulosin demonstrated a
comparable 51% reduction in nonvoiding contrac-
tions. The same study demonstrated inhibition
of human prostate stromal cell proliferation with
vardenafil in vivo.23 Tinel et al.24 utilized a rat
model that demonstrated a PDE-inhibitor dose-
dependent reduction in smooth muscle contraction
of bladder, urethral and prostate strips. A reduction
in bladder nonvoiding contractions was noted in the
rat BOO model after administration of sildenafil and
vardenafil. The same study demonstrated inhibition
of human prostate stromal cell proliferation with
vardenafil in vivo. Interestingly, a recent discovery
was made of PDE5 expression in the striated muscle
of the urethra and levator ani in rats.25 This finding
was surprising, as it was previously believed that
PDE5 was not expressed, or not of relevance,
in striated muscle fibers. The discovery of PDE5
expression in striated muscle of the urethra and
levator ani could lead to better understanding of
urethral relaxation and pelvic floor disorders, both
of which can manifest as LUTS. The exact role of
PDE5 in these striated muscles needs to be further
examined.
Increased smooth muscle contractility
a1-Adrenergic receptors have an important role in
mediating the tone of smooth muscle cells in various
tissues. Various a1-adrenergic receptor subtypes
have been identified in the lower urinary tract,
including a1A and a1D receptors in prostatic
stromal cells,26,27 a1B receptors in epithelial cells,
a1A and a1B receptors in vascular smooth muscle,28
a1A and a1D receptors in the urethra and bladder
and a1D receptors in the detrusor muscle.29 Penile
erection and flaccidity depend on a balance between
contraction and relaxation of the corpus cavernosum
smooth muscle.30 In various forms of ED, the
balance favors smooth muscle contraction rather
than relaxation. Noradrenaline is involved in the
contraction of penile smooth muscle by activating
a1-adrenergic receptors in the penile vasculature
and corpus cavernosum smooth muscle, with
androgens regulating the responsiveness of these
receptors.31 In certain human arteries, a1-receptor
expression increases and the relative proportion of
a1-adrenergic receptor subtypes is modulated by
aging.28 These changes might be happening as well
in the human prostatic, bladder and erectile tissue.
The contractile response of the smooth muscle strips
to phenylephrine was greater for those strips
isolated from the corpus cavernosum of older (460
years) men with ED than for those isolated from
younger (o60 years) men with ED. This marked
difference suggests that aging has a role in adrener-
gic sensitivity in patients with ED.32 Furthermore,
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elevated serum epinephrine levels were found in
men with ED and there was a negative association
between serum levels of epinephrine on the one
hand, and IEFF-5 and IPSS on the other hand. It was
concluded that the potential for an increase in
sympathetic tone may be one of the common denomi-
nators of the two disease processes.33 It has been
suggested that a1-adrenergic receptors are upregulated
in patients with LUTS associated with BPH, resulting
in increased smooth muscle tone in the prostatic
capsule and bladder neck.34 Rat models have demon-
strated an effect on prostatic growth and differentia-
tion through manipulation of autonomic activity.35
Not only can changes at the level of adrenergic
receptor expression and circulating sympathetic
neurotransmitters explain a link between ED and
LUTS, but also changes at the level of the myosin-
actin filament interaction leading to smooth muscle
hypercontractility have further been described
in both diseases. Contraction of smooth muscle is
stimulated by the inhibition of myosin light chain
phosphatase by Rho kinase, and, therefore, provides
a calcium-independent mechanism for smooth mus-
cle contraction. Thus, an abnormally upregulated
Rho-kinase pathway could contribute to a lack
of smooth muscle relaxation, changes in bladder
compliance and thus LUTS. Upregulation of Rho
kinase has indeed been linked to both ED and LUTS
in various studies.36,37 Furthermore, the relaxant
and anti-proliferative effect of Rho-kinase inhibitors
corroborated this finding.38 The suggestion that
BOO induces ED via an upregulation of Rho kinase
in the penis has experimental merit.39 There is also a
possibility that a multisystem dysfunction of Rho
kinase exists and leads to both ED and LUTS.40
Rho kinase has further been shown to have a role in
hypertension and its expression correlates to aging,
which provides a partial explanation not only for
the relationship between LUTS and ED, but also for
the connection of LUTS, ED and hypertension.41
Pelvic atherosclerosis
An additional mechanism is diffuse atherosclerosis
of blood vessels supplying prostate, penis and
bladder.42 In a recent epidemiologic study that
supports this notion, both men and women who
had two risk factors of atherosclerosis (diabetes
mellitus, hypertension, hyperlipidemia and nico-
tine use) had a statistically significant higher
IPSS compared with subjects with one or no risk
factors.43 Another epidemiologic study showed that
men with risk factors for vascular disease are more
likely to have a higher IPSS and a lower IIEF score
than men without risk factors.44 In a prospective
office-based study, a total of 374 male patients with
ED were enrolled to assess if there is an underlying
vascular association between LUTS and ED. The
study concluded that reduced peak systolic velocity
of the cavernous arteries correlates with LUTS in
patients with ED.45 Animal models mimicking
pelvic ischemia and hypercholesterolemia show a
striking similarity in the smooth muscle alterations
of the detrusor muscle and corpora cavernosa. In the
rabbit, chronic ischemia resulted in fibrosis, smooth
muscle atrophy and decreased compliance of the
bladder.46 Similar studies involving the prostate
showed that chronic ischemia resulted in stromal
fibrosis, glandular cystic atrophy and increase in
smooth muscle contractility of the rabbit pros-
tate,47,48 and persistent hypoxia caused penile
fibrosis in the corpus cavernosum tissue. There are
several potential mechanisms to explain these
findings. Chronic ischemia is associated with an
increased production of profibrotic and proapopto-
tic cytokines, such as transforming growth factor-b1,
which correlates with the severity of fibrosis.46
Transforming growth factor-b1 further impairs neu-
rogenic relaxation in the prostate, which appears to
involve the NO pathway (see above), and may result
in a loss of elasticity and an increase in smooth
muscle tone of the prostate.47 In fact, atherosclerosis-
induced pelvic ischemia is likely compatible with
all theories mentioned previously, as it may induce
autonomic nervous system hyperactivity, reduce NOS
expression and upregulate Rho kinase.49
Sex hormones
Androgens have been suggested to have an impor-
tant role in the maintenance of the functional and
structural integrity of the urinary tract. It is possible
that declining testosterone production with aging
contributes to the development of LUTS.50 Andro-
gen receptors have been found to be expressed in the
epithelial cells of the urethra and the bladder of
rabbits and in the urothelium, bladder smooth
muscle, striated muscle cells of the proximal urethra
and in the neurons in the autonomic ganglia of the
prostatic plexus of the male rat.51,52 The role of
testosterone and its metabolites on maintaining the
reflex activity in the pelvic part of the autonomic
nervous system has been demonstrated in rats.53
Upon castration, electrically evoked relaxations
of the smooth muscle of the prostatic urethra were
decreased and this effect was ascribed to an
impaired ability of the smooth muscle to respond
to relaxant agents.54 The effects of testosterone can
be partially explained by the fact that NO produc-
tion is androgen dependent in the urinary tract.
NOS in an earlier study had appeared to be
androgen dependent in the urogenital tract of the
rat.55 This is also true in the erectile apparatus.
Longitudinal data from the Massachusetts Male
Aging Study (MMAS) indicated that serum levels
of total testosterone, dehydroepiandrosterone and
dehydroepiandrosterone sulfate declined, whereas
levels of dihydrotestosterone and sex hormone
binding globulin, luteinizing hormone and folicle-
stimulating hormone increased with advancing
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age.56 A recent study found that low testosterone
levels in clinical BOO correlated negatively with
detrusor pressure.57
Psychological factors
In addition to these four major pathophysiological
associations, psychosocial factors have also been
suggested. Frankel et al.58 reported that urinary
incontinence or painful urination could decrease
social and sexual confidence and thus lead to ED.
Elliott et al.10 suggested that depression could
reduce sexual function. In addition, changes in
lifestyle due to nocturia and disorders of rapid eye
movement sleep phase could lead to ED.12 Whether
having an either LUTS- or ED-related decreased
mood impacts the development of the other disorder
remains to be clarified.
LUTS and ED: effects on clinical
management
At present day, oral agents, including a-adrenergic
blockers either with or without associated anti-
cholinergics are now the standard first-line therapy
for men with bothersome and moderate-to-severe
LUTS.59 5a-Reductase inhibitors are an appropriate
treatment option for patients with LUTS and
evidence of marked prostatic enlargement. If phar-
macological management fails, the classical open, or
more often transurethral resection of the prostate
(TURP) is the recommended treatment.
Impact of surgery for BPH on erectile function
ED following surgical treatments for LUTS and/or
prostatic diseases is not uncommon. A summary for
the sexual side effects of the different therapies for
BPH/LUTS is provided in Table 1.
The estimated incidence of ED following TURP
was 10% in 15 trials (versus 2% for control).59 In
contrast with these findings, the Veterans Affairs
Cooperative Group study on TURP demonstrated
that the incidence of ED in men with moderate
LUTS/BPH who underwent TURP was actually
lower than the incidence in the watchful waiting
group.60 Novel minimally invasive therapies,
including transurethral microwave therapy and
transurethral needle ablation induce sexual dys-
function to a lesser extent than TURP, with a rate of
ED of approximately 3% (versus 3% for therapy and
10% for TURP).59 Data from a number of small
studies suggested that minimally invasive therapies
may be associated with less sexual dysfunction
when compared with TURP.61–63 In a randomized
comparison of TURP with holmium laser enucleat-
ing of the prostate, holmium laser enucleating of the
prostate was not associated with worsening erectile
function after surgery and there was no difference
compared with TURP.64
A number of studies related to Greenlight
laser vaporization of the prostate describe no
influence65–67 or even improvement68 of erectile
function. In contrary to the previously mentioned
studies, in another study in a group of preopera-
tively potent patients (IIEF-5418), a significant
negative impact on erectile function following the
Greenlight procedure was observed.69 The reason for
this discrepancy between studies remains unclear.
One possible explanation might be use of definitions
of potency between these studies.70 Open surgery is
associated with a high incidence of sexual dysfunc-
tion, reaching 10% for ED and 65% for ejaculatory
dysfunction.71 However, another study examining
60 men undergoing open prostatectomy for BPH did
not note any change in sexual function scores as a
result of surgery, suggesting that either prostat
ectomy does not affect sexual function or that any
deterioration as a result of the procedure was offset
by a reduction in sexual dysfunction related to the
observed improvement in LUTS.72 The latter argu-
ment is putatively applicable to all (surgical and
Table 1 Therapies for benign prostatic hyperplasia: estimated
incidence rates of sexual adverse events59
Ejaculation Erectile
dysfunction
a-Blockers
Alfuzosin 3% (1–6)
Doxazosin 0% (0–2) 4% (1–8)
Tamsulosin 10% (6–15) 4% (1–8)
Terazosin 1% (1–2) 5% (3–8)
Hormonal
Finasteride 4% (3–5) 8% (6–11)
Combination
Alfuzosin/finasteride 1% (0–2) 8% (5–11)
Doxazosin/finasteride 3% (2–6) 10% (7–14)
Terazosin/finasteride 7% (5–10) 9% (1–13)
Placebo 1% (1–1) 4% (3–5)
Thermal-based therapies
Prostatron version 2.0 TUMT 5% (4–8) 3% (1–5)
Prostatron version 2.5 TUMT 16% (2–49) 1% (0–8)
Targis TUMT 5% (2–10)
TUNA 4% (1–10) 3% (1–6)
Watchful waiting 21% (17–26)
Sham (control) 2% (0–5) 2% (1–6)
TURP 65% (56–72) 10% (7–13)
Holmium laser 59% (37–79) 3% (0–12)
Transurethral laser coagulation 17% (12–24) 6% (3–12)
TUIP 18% (12–25) 13% (6–23)
TURP—electrovaporization 65% (43–83) 8% (4–12)
Transurethral laser vaporization 42% (21–66)
Open prostatectomy 61% (35–84)
Abbreviations: TUIP, transurethral incision of the prostate;
TUMT, transurethral microwave thermotherapy of the prostate;
TUNA, transurethral needle ablation of the prostate; TURP,
transurethral resection of the prostate.
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medical) therapies for LUTS, as it is complicated to
distinguish between erectile function changes due
to therapy versus due to relieve of LUTS complaints.
Impact of pharmacological treatment of LUTS on ED
Pharmacological treatments of BPH are classically
associated with a relatively lower risk of consequen-
tial sexual dysfunction compared with surgical
intervention.73 There has been some speculation
that a-blocker therapy may result in improvements
in sexual function as a result of improvements in
LUTS. Again, as was explained above, it is difficult
to determine whether this treatment improves LUTS
and subsequently ED, or whether the treatment
targets both processes by targeting a shared patho-
physiology. In a Korean study, the correlation
between LUTS and sexual function was investigated
in 365 men with BPH.74 After 3 months of treatment
with a-blockers (n¼ 304), they were assessed again
to evaluate the effectiveness of the treatment.
Various parameters of LUTS correlated significantly
with the total and each domain of IIEF-5. Further-
more, changed urine flow rates correlated signifi-
cantly with the improvement in total IIEF-5 and the
EF domain. One open-label study assessed the effect
of alfuzosin on sexual function in 3076 men over
a 1-year period.75 At the end point, alfuzosin
significantly improved the total IPSS and urinary
bother score versus baseline, and in those men with
sexual dysfunction, there were significant improve-
ments in rigidity of erection, amount of ejaculate
and pain/discomfort on ejaculation versus baseline.
These improvements were of a greater magnitude in
men with severe LUTS or bother at baseline. In
another study examining a-blocker use and sexual
dysfunction among men participating in a popula-
tion-based cohort, it was concluded that the use
of a-blockers for LUTS was associated with a
decreased risk of sexual dysfunction. Improvement
in sexual function correlated with the improvement
in LUTS more strongly among those using
a-blockers.76 In clinical trials involving sildodosin,
the adverse effects were only ejaculatory distur-
bances and only 2.8% of patients discontinued
treatment due to this adverse effect.77 Placebo-
controlled studies of 5a-reductase inhibitors have
shown that ED occurs in 7–8% of men (placebo,
4–5%), decreased libido in 4–6% (placebo, 2–3%)
and abnormal ejaculation in 1–2% (placebo, o1%).
These events are more prominent in the first months
of therapy, and the incidence tends to diminish with
time.78–81 The Alfuzosin-Finasteride (ALFIN) study
demonstrated that alfuzosin had little or no impact
on sexual function, whereas finasteride and combi-
nation therapy (alfuzosin and finasteride) caused
impairment of erectile and ejaculatory function.82,83
These findings have also been replicated in the
larger scale, placebo-controlled Medical Therapy of
Prostatic Symptoms study.79
Impact of pharmacological treatment of ED on
LUTS: PDE5 inhibitors
Four possible pathophysiologic mechanisms have
been described that may explain a potential role of
PDE5-inhibitor therapy in LUTS. PDE5 inhibitors
facilitate smooth muscle relaxation by inhibiting the
breakdown of cyclic guanosine monophosphate,
which is known as the second messenger of NO.
Cyclic guanosine monophosphate subsequently
phophorylates several other targets, leading to
depletion of intracellular calcium. This leads to a
dissociation of calmodulin from myosin light
chain kinase and its inactivation (phosphorylation).
Myosin is subsequently dephosphorylated by
myosin light chain phosphatase, detaching from
actin. This cascade ultimately results in smooth
muscle relaxation. Effects and expression of PDE5
have been shown in the bladder, prostate and
urethra. Beside that, PDE5 inhibitors have been
shown to counter autonomic hyperactivity (which is
mediated through increased norepinephrine and
endothelin levels). Rho-kinase’s effects are mediated
in part by these same second messengers, and it can
be affected also by PDE5 inhibitors. Pelvic athero-
sclerosis and ischemia have their effects via these
concepts.84
Several randomized, placebo-controlled studies to
assess the effect of PDE inhibitors on LUTS using
sildenafil, vardenafil and tadalafil were conducted.
The study employing sildenafil used a 12-week,
double-blinded, placebo-controlled approach in 369
men over 45 years of age who had IIEF scores under
26 (on erectile function domain) and IPSS scores
411.85 The 189 men receiving sildenafil had
significant improvement in IPSS and IIEF scores.
BPH index, IPSS QoL score, total self-esteem and
relationship questionnaire scores and overall treat-
ment satisfaction were all significantly improved in
the treatment arm. However, no difference in
urinary flow rates was noted between the treatment
and placebo arms.
The vardenafil study included 222 men aged
45–64 years who had an IPSS411 at the time of
randomization between 8 weeks treatment of 10mg
twice daily versus placebo.86 No history of ED was
required for inclusion in the study. Vardenafil
treatment resulted in a decrease in IPSS of 2.3
greater than placebo. Significant improvement was
noted in QoL, irritative and obstructive IPSS sub-
scores and IIEF scores in the treatment group. As in
the sildenafil trial, no statistically significant
improvement in Qmax was found in comparison
with placebo. Post-voiding residual urine volume
did not significantly change in the treatment group.
In the tadalafil study, following a 4-week, single-
blind, placebo run-in, 281 men were randomly
assigned to 5mg tadalafil daily for 6 weeks, followed
by dose escalation to 20mg for 6 or 12 weeks of
placebo.87 Tadalafil significantly improved IPSS,
although no differences were seen in uroflow
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parameters between the placebo and treatment
groups. Significant improvements were recorded in
both obstructive and irritative IPSS, QoL measures
and IIEF scores.
Roehrborn et al.88 performed a dose-finding study
using tadalafil for LUTS in 1058 men. The patients
were assigned to placebo or one of four different
tadalafil dosing regimens (2.5, 5, 10 or 20mg daily).
Significant improvement of LUTS was observed in
the 5-mg group. Urinary flow rates did not show
any change at any dosage level in comparison
with placebo. Increasing the tadalafil dosage
45mg (10 or 20mg) resulted in similar improve-
ments in IPSS, but at the cost of a higher incidence
of adverse effects. The sexually active men (55%)
showed a significant improvement in IIEF scores.
Tadalafil has its therapeutic effects through bene-
ficial actions on smooth muscle relaxation, smooth
muscle and endothelial cell proliferation, nerve
activity and tissue perfusion.89
Significant improvement in IPSS after PDE5-
inhibitor therapy compared with placebo was
reported in all clinical studies with the magnitude
of IPSS improvement comparable with those
reported in previous a-blocker studies. Interestingly,
none of the studies showed a significant effect of
PDE5-I on peak urinary flow rate. This may be
explained by the hypothesis that PDE5 inhibitors
primarily affect detrusor activity rather than the
BOO.90 A study by Gacci et al.91 in men with
neurogenic bladders secondary to spinal cord injury
showed that vardenafil treatment resulted in sig-
nificant improvements in maximum detrussor pres-
sure, total capacity and volume triggered bladder
spasms.
A recent study by Dmochowski et al.92 examined
LUTS and urodynamic parameters in 200 men
(baseline IPSS¼ 13) randomized to tadalafil
(20mg) treatment or placebo for 12 weeks. Although
no difference was noted in urodynamic parameters
after treatment (including BOO index), IPSS
improved significantly in the treatment group
compared with placebo. Additionally, the propor-
tion of obstructed patients in the treatment group
decreased, whereas the proportion in the placebo
group increased.
A new PDE-5 inhibitor, udenafil, is approved for
use in South Korea and the United Kingdom and
currently under further investigation in the United
States.93 A trial combining udenafil and an
a-blocker in men with ED concomitant with BPH
and LUTS showed that the co-administration of
udenafil and an a-blocker in patients with both BPH
and ED was safe, and patients showed significant
improvements in both LUTS and ED.94 Two more
studies investigating the combination of a-blocker
and PDE-5 inhibitor to treat LUTS and ED con-
cluded that the combination of the two drugs
is safe and more effective than monotherapy
with either agent to improve both voiding and
sexual dysfunction in men with LUTS suggestive
of BPH.95,96
Effects of testosterone used for treatment of
hypogonadism on LUTS
A number of studies involving the use of testo
sterone for ED or late onset hypogonadism, investigated
the effects of testosterone administration to
elderly men on symptoms of LUTS. Saad et al.97
described the effects of administration of parenteral
testosterone undecanaote over 12 months. There
were positive clinical effects of administration of
testosterone suppletion on the IPSS as well as on
parameters of the metabolic syndrome, progressing
over the 12-month study period. Since the effects
were progressive over the 12 months of the study, it
is likely that the effects take time to occur following
testosterone administration. The same authors con-
cluded in a separate study that there were positive
clinical effects of administration of testosterone gel
on the IPSS and also on parameters of the metabolic
syndrome, and there was a significant further
improvement of the IPSS when testosterone
undecanaote was administered after 9 months of
administration of testosterone gel when plasma
testosterone levels increased to higher levels than
with testosterone gel.98
This can be explained by the decreased levels
of free and total testosterone associated with the
presence of metabolic syndrome, as well as with
many of its components: obesity, dyslipidemia and
insulin resistance. Metabolic syndrome can contri-
bute to testosterone deficiency through decreased
sex hormone binding globulin levels; suppression of
gonadotrophin release or Leydig cell testosterone
production; and cytokine-mediated inhibition of
testicular steroid production.99 Testosterone defi-
ciency may be a pathophysiological mechanism
connecting LUTS and ED with the metabolic
syndrome in men. Decreased testosterone can cause
LUTS through relaxations of the smooth muscle
of the prostatic urethra and bladder (see above).
Regarding ED, in addition to downregulation of
many pro-erectile molecular mechanisms as (cyclic
guanosine monophosphate) formation, decreased
testosterone levels upregulate corpus cavernosum
smooth muscle contractile signaling and down-
regulates corpus cavernosum smooth muscle relaxa-
tion pathways synergizing to produce ED.100 Haide
et al.101 investigated the effects of normalization of
testosterone levels in hypogondal elderly men on
LUTS. Along with the improvement of the metabolic
syndrome upon testosterone administration, there
was also an improvement of the IPSS and residual
bladder volume of urine. The delayed and progres-
sive effect of testosterone on LUTS is intriguing.
More studies at molecular level are needed
to elucidate the mechanism as well as planning
larger clinical trials.
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Conclusions
LUTS and ED are common disorders in aging men,
which are independently associated to one another.
The two disorders share certain pathophysiologic
mechanisms and this association has many clinical
implications. It is recommended that men present-
ing with LUTS should be evaluated for sexual
dysfunction and ED in particular, and those pre-
senting with sexual dysfunction should be evalu-
ated for LUTS. Patients should further be screened
for risk factors for underlying disorders. In treating
LUTS, the presence or absence of sexual dysfunc-
tion may affect the choice of therapy, especially
once patient preferences are considered. For this
indication, the introduction of PDE-5 inhibitors is
gaining acceptance. In patients with obstructive
LUTS, the association of an a-blocker may be of
benefit. Ongoing research is further elucidating
these complex interactions, and might hold promise
for future therapy of men suffering from both LUTS
and ED.
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